[1]邓婵翠,石蓓,刘志江.冠状动脉支架内再狭窄的治疗现状及进展[J].心血管病学进展,2015,(6):747-751.[doi:10.3969/j.issn.1004-3934.2015.06.023]
　DENG Chancui,SHI Bei,LIU Zhijiang.Current Treatment and Prospect of In-stent Restenosis[J].Advances in Cardiovascular Diseases,2015,(6):747-751.[doi:10.3969/j.issn.1004-3934.2015.06.023]
点击复制

冠状动脉支架内再狭窄的治疗现状及进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2015年6期
页码:
747-751
栏目:
综述
出版日期:
2016-06-20

文章信息/Info

Title:
Current Treatment and Prospect of In-stent Restenosis
作者:
邓婵翠; 石蓓; 刘志江
遵义医学院第一附属医院心血管内科,贵州 遵义 563003
Author(s):
DENG Chancui; SHI Bei; LIU Zhijiang
Department of Cardiology,The First Affiliated Hospital of Zunyi Medical College,Zunyi 563003,Guizhou,China
关键词:
冠状动脉再狭窄;  新生动脉粥样硬化斑块;  支架;  现状
Keywords:
coronary restenosis;  neoatherosclerosis;  stents;  status
分类号:
R541.4
DOI:
10.3969/j.issn.1004-3934.2015.06.023
文献标志码:
A
摘要:
药物洗脱支架在显著降低再狭窄发生率的同时,增加了晚期支架内血栓发生风险及加速了新生内膜动脉粥样硬化。过去认为再狭窄的发生主要是由于新生内膜过度增殖,但新近研究发现,新生动脉粥样硬化斑块可能扮演了重要的病理生理作用,而晚期支架内血栓形成和新生内膜动脉粥样硬化是晚期支架失败的重要原因。现对近年来冠状动脉支架内再狭窄的治疗现状及进展做一综述。
Abstract:
Drug-eluting stent have dramatically reduced restenosis rates, however, their use has been associated with an increased risk of late or very late stent thrombosis and accelerated neointimal atherosclerosis. In-stent restenosis mainly results from aggressive neointimal proliferation,but recent data also suggests that in-stent neoatherosclerosis may play an important pathophysiological role, while late stent thrombosis and neointimal atherosclerosis are major contributors to late stent failure. In this review,we discuss currently available therapeutic strategies and prospects for the management of patients with in-stent restenosis.

参考文献/References:

[1] Mehran R,Dangas G,Abizaid AS,et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome[J].Circulation,1999,100(18):1872-1878.
[2] Habib A,Finn AV. Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration[J].Pharmacol Res,2015,93:22-27.
[3] Tada T,Byrne RA,Simunovic I,et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients[J]. J Am Coll Cardiol Interv,2013,6(12):1267-1274.
[4] Cassese S,Byrne RA,Tada T,et al. Incidence and predictors of restenosis after coronary stenting in 10,004 patients with surveillance angiography[J]. Heart,2014,100(2):153-159.
[5] Otsuka F,Vorpahl M,Nakano M,et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans[J]. Circulation,2014,129(2):211-223.
[6] Takano M,Yamamoto M,Inami S,et al. Appearance of lipid-laden intima and neovascularization after implantation of bare-metal stents extended late-phase observation by intracoronary optical coherence tomography[J].J Am Coll Cardiol,2009,55(1):26-32.
[7] Kang SJ,Mintz GS,Park DW,et al.Tissue characterization of in-stent neointima using intravascular ultrasound radio frequency data analysis[J]. Am J Cardiol,2010,106(11):1561-1565.
[8] Kang SJ,Lee CW,Song H,et al. OCT analysis in patients with very late stent thrombosis[J].JACC Cardiovasc Imaging,2013,6(6):695-703.
[9] Nagoshi R,Shinke T,Otake H,et al. Qualitative and quantitative assessment of stent restenosis by optical coherence tomography:comparison between drug-eluting and bare-metal stents[J].Circ J,2013,77(3):652-660.
[10] Kang SJ, Mintz GS,Akasaka T, et al. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation[J]. Circulation,2011,123(25):2954-2963.
[11] Habara M,Terashima M,Nasu K,et al.Morphological differences of tissue characteristics between early, late, and very late restenosis lesions after first generation drug-eluting stent implantation:an optical coherence tomography study[J]. Eur Heart J Cardiovasc Imaging,2013,14(3):276-284.
[12] Kitabata H,Tanaka A,Kubo T,et al. Relation of microchannel structure identified by optical coherence tomography to plaque vulnerability in patients with coronary artery disease[J].Am J Cardiol,2010,105(12):1673-1678.
[13] Campo G,Tebaldi M,Vranckx P,et al.Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis:a PRODIGY trial substudy(Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia)[J]. J Am Coll Cardiol,2014,63(6):506-512.
[14] Piccolo R,Galasso G,Piscione F,et al. Meta-analysis of randomized trials comparing the effectiveness of different strategies for the treatment of drug-eluting stent restenosis[J].Am J Cardiol,2014,114:1339-1346.
[15] Ozaki Y,Lemos PA,Yamaguchi T,et al.A quantitative coronary angiography-matched comparison between a prospective randomised multicentre cutting balloon angioplasty and bare metal stent trial(REDUCE Ⅲ)and the Rapamycin-Eluting Stent Evaluation At Rotterdam Cardiology Hospital(RESEARCH)study[J].EuroIntervention,2010,6(3):400-406.
[16] Alfonso F,Zueco J,Cequier A, et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis[J].J Am Coll Cardiol,2003,42(5):796-805.
[17] Kastrati A,Mehilli J,von Beckerath N,et al.Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis:a randomized controlled trial[J]. JAMA,2005,293(2):165-171.
[18] Alfonso F,Pérez-Vizcayno MJ,Hernandez R,et al. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis:results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective SirolimusEluting Stenting(RIBS-Ⅱ)trial[J].J Am Coll Cardiol,2006,47(11):2152-2160.
[19] Mehilli J,Byrne RA,Tiroch K,et al.Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2(Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2)study[J].J Am Coll Cardiol,2010,55(24):2710-2716.
[20] Alfonso F,Pérez-Vizcayno MJ, Dutary J,et al. Implantation of a drug-eluting stent with a different drug(switch strategy)in patients with drug-eluting stent restenosis. Results from a prospective multicenter study(RIBS Ⅲ [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent])[J]. JACC Cardiovasc Interv, 2012,5(7):728-737.
[21] Scheller B,Hehrlein C,Bocksch W,et al.Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter[J].N Engl J Med,2006,355(20):2113-2124.
[22] Unverdorben M,Vallbracht C,Cremers B,et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis[J]. Circulation,2009,119(23):2986-2994.
[23] Alfonso F,Pérez-Vizcayno MJ,Cárdenas A,et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent in-stent restenosis: the RIBS V Clinical Trial[J]. J Am Coll Cardiol,2014,63(14):1378-1386.
[24] Habara S,Mitsudo K,Kadota K,et al. Effectiveness of paclitaxel eluting balloon catheter in patients with sirolimus-eluting stent restenosis[J]. J Am Coll Cardiol Interv,2011,4(2):149-154.
[25] Rittger H,Brachmann J,Sinha AM,et al.A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study[J]. J Am Coll Cardiol,2012,59(15):1377-1382.
[26] Xu B,Gao R,Wang J,et al. A prospective, multicenter, randomized trial of paclitaxel coated balloon versus paclitaxel-eluting stent for the treatment of drug eluting stent in-stent restenosis: results from the PEPCAD China ISR trial[J]. J Am Coll Cardiol Interv,2014,7(2):204-211.
[27] Habara S, Iwabuchi M,Inoue N,et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis[J]. Am Heart J,2013,166(3):527-533.
[28] Byrne RA,Neumann FJ,Mehilli J,et al.Paclitaxel-eluting balloons,paclitaxel-eluting stents,and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent(ISAR-DESIRE3): a randomised, open-label trial[J]. Lancet,2013,381(9865):461-467.

备注/Memo

备注/Memo:
作者简介:邓婵翠(1988—),在读硕士,主要从事冠心病介入研究。Email:714662148@qq.com 通信作者:石蓓,主任医师,硕士生导师,主要从事冠心病介入与再狭窄研究。Email:shibei2147@163.com
更新日期/Last Update: 2016-06-20